MJ Fox Foundation Gives Therapeutic Pipeline Award to Progenra, Supporting Work on New Therapies

Related Articles:

• MJ Fox Foundation Gives Therapeutic Pipeline Award to Progenra, Supporting Work on New Therapies December 21, 2018 The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has granted a 2018 Therapeutic Pipeline Award to Progenra to support the company’s development of small molecule treatment candidates for Parkinson’s disease. “Progenra is pleased to have been selected by The Michael J. Fox Foundation to contribute to bringing Parkinson’s and other major neurodegenerative diseases under control by introducing new therapeutic…
• Michael J. Fox Foundation Offering $7.5M in Funding for Parkinson’s Research Projects August 8, 2018 The Michael J. Fox Foundation is continuing to support the advancement of Parkinson’s disease research by investing up to $7.5 million in projects proposed by investigators, the nonprofit recently announced. Funding will be considered for projects aimed at the following four areas: exploring new biological targets for therapeutic development; identifying biomarkers to objectively measure disease progression; testing potential new treatments; and…
• Rodin Receives $600,000 Michael J. Fox Foundation Grant for Parkinson’s Research November 27, 2017 The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded $600,000 to Rodin Therapeutics to advance new research in Parkinson’s disease. One of the most prominent features in Parkinson’s is the loss of dopaminergic neurons in a brain regions called substantia nigra. These cells produce dopamine, the chemical messenger that coordinates movement. Loss of dopamine (and dopaminergic synapses) causes neurons to start communicating abnormally,…
• Fox Foundation Awards AC Immune New Grant to Advance Alpha-Synuclein Imaging Agent September 9, 2019 The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded AC Immune a new grant to further the development of tracer compounds for Parkinson’s disease (PD). Specifically, this award continues MJFF support for AC Immune’s alpha-synuclein positron-emission tomography (PET) tracer program, aiming for an accurate imaging agent of the alpha-synuclein protein clumps in nerve cells of the brain that are…
• Michael J. Fox Foundation Announces New $7M Initiative to Support Parkinson’s Research, Therapy Development March 22, 2018 The Michael J. Fox Foundation (MJFF) announced a new $7 million funding program to support Parkinson’s disease research and accelerate development of new therapeutic targets and biomarkers. Through the program, researchers can request project funding in four major research areas. The organization is now accepting pre-proposals through May 2018, with funding anticipated by November 2018. “We are working diligently toward breakthroughs…
• Michael J. Fox Foundation Grants $7.7M for New Parkinson’s Research July 6, 2018 New research projects focused on better ways to monitor and treat Parkinson’s disease were awarded funding recently by the Michael J. Fox Foundation (MJFF). From more than 200 funding proposals submitted to its 2018 spring funding program, 39 projects were funded. Selected projects primarily come from the United States (19), but funding also was granted to projects in 11 other…
• Sirion and Denali Collaborating to Develop Gene Therapies for Neurodegenerative Diseases January 14, 2019 Sirion Biotech and Denali Therapeutics have agreed to partner on the development of gene therapies for Parkinson’s disease and other neurodegenerative disorders. According to the license and collaboration agreement, the two companies will pursue the development of harmless, next-generation adeno-associated viral vectors (AAV) able to cross the blood-brain barrier — a semipermeable membrane that protects the brain against the external environment. Besides Parkinson’s,…
• Cantabio’s Therapy Candidate Targeting DJ-1 Protein Shows Potential in Parkinson’s Mouse Model August 2, 2018 Cantabio Pharmaceuticals’ small molecule therapeutic candidate was able to protect dopamine-producing brain cells from death and prevent the loss of dopamine in a mouse model of Parkinson’s disease, according to preclinical data. The compound targets DJ-1, a protein whose loss is associated with the onset of several diseases, including Parkinson’s, Alzheimer’s, and amyotrophic lateral sclerosis (ALS). “The results provide substantial validation of…
• New drug MM-201 could reverse the course of neuro-degenerative disease like Parkinson’s and Alzheimer’s November 9, 2015 A cure for Parkinson’s Disease and Alzheimer’s may be on the horizon as doctors and researchers work furiously to learn more about what causes it — and ways to stop the disease from getting worse. Right now, there are an estimated 50 to 60,000 new cases of Parkinson’s Disease diagnosed each year (in the USA). A Seattle-based biotechnology company has…
• New drug MM-201 could reverse the course of neuro-degenerative disease like Parkinson’s and Alzheimer’s November 9, 2015 A cure for Parkinson’s Disease and Alzheimer’s may be on the horizon as doctors and researchers work furiously to learn more about what causes it — and ways to stop the disease from getting worse. Right now, there are an estimated 50 to 60,000 new cases of Parkinson’s Disease diagnosed each year (in the USA). A Seattle-based biotechnology company has…
• New drug MM-201 could reverse the course of neuro-degenerative disease like Parkinson’s and Alzheimer’s November 9, 2015 A cure for Parkinson’s Disease and Alzheimer’s may be on the horizon as doctors and researchers work furiously to learn more about what causes it — and ways to stop the disease from getting worse. Right now, there are an estimated 50 to 60,000 new cases of Parkinson’s Disease diagnosed each year (in the USA). A Seattle-based biotechnology company has…
• First DUB Enzymes Identified by Partnership as Potential Therapeutic Targets for Parkinson’s and Alzheimer’s December 11, 2019 Mission Therapeutics and AbbVie have identified several molecules, called deubiquitylating enzymes, or DUBs, that may be potential therapeutic targets to treat Parkinson’s and Alzheimer’s diseases. This comes after the two companies announced a collaboration last year to identify DUB inhibitors to treat these neurodegenerative disorders. Identifying potential targetable DUBs is the first step in developing specific inhibitors. In Parkinson’s disease,…
• Parkinson’s Foundation Awarding 53 Grants Worth $6.2M to Advance Research and Disease Understanding August 20, 2018 The Parkinson’s Foundation announced that it investing $6.2 million across 53 research grants, part of its commitment to advancing promising work into the disease. The grants will support Parkinson’s clinical trials and research centers. They also include career development and fellowships for scientists working in multiple aspects of related research. “Our goal at the Parkinson’s Foundation is to increase funding for researchers making significant…
• MJFF and Silverstein Foundation Jointly Award $3M Supporting Research into GBA Mutations February 26, 2019 Some 10 percent of Parkinson’s patients carry a mutation in the GBA gene, making it the most common genetic risk for this disease. With a goal of learning more about these mutations, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and the Silverstein Foundation for Parkinson’s with GBA is awarding $3 million in grants. Specifically, projects chosen aim to shed…
• Biogen, C4 Therapeutics Working to Treat Parkinson’s by ‘Naturally’ Degrading and Clearing Proteins January 8, 2019 Biogen and C4 Therapeutics (C4T) have joined efforts to develop therapies using a cell’s natural protein degradation system as a way of treating neurological diseases such as Alzheimer’s and Parkinson’s. This agreement allows the two to combine Biogen’s expertise in neuroscience and therapy development with C4T’s knowledge and research work into targeted protein degradation, or the breaking down of faulty…
• Mission, Abbvie Partner to Develop DUB Enzyme Inhibitors for Parkinson’s and Alzheimer’s November 26, 2018 Mission Therapeutics and AbbVie have established a new partnership aimed at developing specific inhibitors targeting deubiquitylating enzymes, or DUBs, for the treatment of Alzheimer’s and Parkinson’s diseases. DUBs are a large family of important enzymes that regulate the protein degradation process, some of which are involved in the destruction of misfolded and potentially toxic proteins known to be associated with human diseases. Although…
• 2 New Rat Models Opening to Researchers Through Horizon-Fox Foundation Partnership November 3, 2017 Horizon Discovery, in a collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), has developed two new genetic rat models that may help scientists better understand alpha-synuclein‘s role in brain function and in the development of Parkinson’s disease (PD). Alpha-synuclein is the main molecular component of Lewy bodies, protein clumps that are the hallmark of Parkinson’s. But it is…
• AC Immune Obtaining More Fox Foundation Funding to Continue Developing PET Tracers for Diagnosing Parkinson’s October 4, 2017 AC Immune is receiving additional funding from the Michael J. Fox Foundation for Parkinson’s Research to continue developing positron emission tomography (PET) tracers for alpha-synuclein, a protein linked to Parkinson’s disease. The idea behind the project is to use alpha-synuclein as a biomarker of Parkinson’s. The PET tracers will help identify how much of the protein is in the brain, and where. The…
• MJFF Grant Will Help Inflazome Develop Brain-imaging Probe for Parkinson’s Research March 27, 2019 The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has granted more than $1 million to Inflazome to fund the development of a brain-imaging probe that may help track progression of Parkinson’s and develop new therapies for the disease. The funding will help develop a positron emission tomography (PET) tracer specific to a cellular sensor of stress known as the NLRP3 inflammasome, and…
• Charles River Laboratories, Michael J. Fox Foundation Extend Research Partnership May 15, 2018 Charles River Laboratories International and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) extended their collaboration to accelerate the discovery of Parkinson’s disease therapies. The extension covers grants from MJFF to characterize two animal models of Parkinson’s — one where mice do not express alpha-synuclein (knockout), and another where mice express the Parkinson’s-associated alpha-synuclein mutant A53T (knockin). Alpha-synuclein is the major…